Get access

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system

Authors


* Sakae Tanaka
Department of Orthopaedic Surgery
Faculty of Medicine
The University of Tokyo
7-3-1 Hongo
Bunkyo-ku
Tokyo 113-0033, Japan
Tel.: +81 3 3815 5411x33376
Fax: +81 3 3818 4082
E-mail: tanakas-ort@h.u-tokyo.ac.jp

Abstract

Summary:  Osteoclasts are primary cells for physiological and pathological bone resorption, and receptor activator of nuclear factor-κB ligand (RANKL) is critically involved in the differentiation, activation, and survival of these cells. Recently, therapeutics for pathological bone destruction targeting RANKL pathways has attracted a great deal of attention. Herein, we review the recent advances in the research on osteoclast biology and discuss the advantages and disadvantages of anti-RANKL therapies.

Ancillary